|
NCT05293197
|
Phase I Trial Assessing the Safety of the Repeated Ultrasound-induced Opening of the Blood-brain Barrier in Pediatric Patients With Refractory Supra-tentorial Malignant Brain Tumors Before Chemotherapy Administration
|
En recrutement
|
13 septembre 2025
|
|
NCT06660654
|
REJOICE-PanTumor01: A Phase 2, Multicenter, Open-Label, Pan-Tumor Trial to Evaluate Efficacy and Safety of Raludotatug Deruxtecan (R-DXd) in Participants With Advanced/Metastatic Solid Tumors
|
En recrutement
|
12 août 2025
|
|
NCT06902883
|
Study on the Effectiveness and Comfort of Innovative Solutions for the Internal Transport of Patients in Wheelchairs in a Hospital Setting (PreDoPTI)
|
En recrutement
|
09 août 2025
|
|
NCT06551324
|
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PF-06821497 (MEVROMETOSTAT) IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE (MEVPRO-1)
|
En recrutement
|
08 août 2025
|
|
NCT06867705
|
Digital Monitoring With Patient-Reported Outcomes in Cancer Care: A Randomized Controlled Trial RC - 102 (Resilience Care - 102)
|
En recrutement
|
02 août 2025
|
|
NCT04181203
|
An Open Label, Randomized, Phase III Study, Evaluating the Efficacy of a Combination of Apalutamide With Radiotherapy and LHRH Agonist in High-risk Postprostatectomy Biochemically Relapsed Prostate Cancer Patients
|
En recrutement
|
31 juillet 2025
|
|
NCT06452277
|
A Phase 3 Open-label, Randomized, Active-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Orally Administered BAY 2927088 Compared With Standard of Care as a First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With HER2-activating Mutations (SOHO-02)
|
En recrutement
|
30 juillet 2025
|
|
NCT06799533
|
AN OPEN-LABEL PHASE 1 STUDY TO INVESTIGATE PF-08046031 IN ADULTS WITH ADVANCED MELANOMA AND OTHER SOLID TUMORS
|
En recrutement
|
30 juillet 2025
|
|
NCT06875310
|
A Randomized, Double-Blind, Phase 3 Trial of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
|
En recrutement
|
25 juillet 2025
|
|
NCT06637423
|
A Phase 1/2 Open-label Clinical Study to Evaluate the Safety and Efficacy of Intravesical Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (NMIBC)
|
En recrutement
|
22 juillet 2025
|
|
NCT05128825
|
A Phase 2 Open-Label, Multicenter Study To Evaluate Efficacy And Safety Of ZN-c3 In Subjects With High-Grade Serous Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer (DENALI / ZN-c3-005 / GOG-3066)
|
En recrutement
|
18 juillet 2025
|
|
NCT06305767
|
A Phase 1/2 Study of V940 Plus Pembrolizumab With or Without Enfortumab Vedotin in Muscle-Invasive Urothelial Carcinoma (MIUC) (INTerpath-005)
|
En recrutement
|
15 juillet 2025
|
|
NCT04905069
|
Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer Being Treated With Stereotactic Body Radiotherapy
|
En recrutement
|
01 juillet 2025
|
|
NCT06625970
|
A Randomized Phase III Trial With a Factorial Design Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse, From the Prostate Cancer Consortium in Europe (PEACE)
|
En recrutement
|
27 juin 2025
|
|
NCT06691984
|
A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Chemotherapy
|
En recrutement
|
27 juin 2025
|
|
NCT04057209
|
VoiceS: Voice Quality After Transoral CO2-Laser Surgery Versus Single Vocal Cord Irradiation for Unilateral Stage 0 & I Glottic Larynx Cancer - A Randomized Phase III Trial
|
En recrutement
|
25 juin 2025
|
|
NCT06840782
|
First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients: a Randomized, Multicentre, Open-label Phase III Study
|
En recrutement
|
24 juin 2025
|
|
NCT06326190
|
177Lu-DOTATATE for Recurrent Meningioma: a Randomized Phase II Study
|
En recrutement
|
24 juin 2025
|
|
NCT04898634
|
A Phase 1 Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer
|
En recrutement
|
24 juin 2025
|
|
NCT06715241
|
A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL CANCERS (COLIBRI-2)
|
En recrutement
|
13 juin 2025
|
|
NCT06772623
|
An Open-label Multi-Cohort Phase 1b/2 Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination With Budigalimab in Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease and No Actionable Genomic Alterations
|
En recrutement
|
10 juin 2025
|
|
NCT06511674
|
Vulnerability and Risk of Neuropathic Pain in Cancer: Validation of a Predictive Tool to Optimize Treatment.
|
En recrutement
|
03 juin 2025
|
|
NCT06305754
|
A Randomized, Open-label, Phase 3 Study of MK-2870 vs. Platinum Doublets in Participants With EGFR-mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors
|
En recrutement
|
31 mai 2025
|
|
NCT06162221
|
A Platform Study of RAS(ON) Inhibitors in Patients With RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)
|
En recrutement
|
31 mai 2025
|
|
NCT06706401
|
A Multicenter, Randomised 2*2 Factorial Design Comparing Standard to Reduced-target Volume Radiotherapy With or Without All-trans Retinoic Acid (ATRA) in Patients With Lateralised Oropharyngeal, Laryngeal and Hypopharyngeal Squamous Cell Carcinoma.
|
En recrutement
|
29 mai 2025
|
|
NCT06567015
|
Phase I/II First-In-Human Open-label Trial to Assess Safety and Efficacy of STX-241 in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Resistant to EGFR Tyrosine Kinase Inhibitors (TKIs).
|
En recrutement
|
28 mai 2025
|
|
NCT04936178
|
A Multicenter Phase 1, Open-Label Study of NB003 to Assess Safety, Tolerability, Pharmacokinetics and Efficacy in Patients With Advanced Malignancies
|
En recrutement
|
24 mai 2025
|
|
NCT05911295
|
An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination With Pembrolizumab Versus Chemotherapy in Subjects With Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma That Expresses HER2 (IHC 1+ and Greater)
|
En recrutement
|
23 mai 2025
|
|
NCT06472245
|
A Randomised, Open-label, Phase 3 Trial Comparing the Efficacy and Safety of OSE2101 Versus Docetaxel in HLA-A2 Positive Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) With Secondary Resistance to Immune Checkpoint Inhibitor (ARTEMIA)
|
En recrutement
|
21 mai 2025
|
|
NCT06190951
|
A Phase 2 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma
|
En recrutement
|
15 mai 2025
|
|
NCT03821935
|
A Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Subjects With Locally Advanced or Metastatic Solid Tumors
|
En recrutement
|
14 mai 2025
|
|
NCT06646276
|
A Randomized, Double Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012+Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide vs Atezolizumab in Combination With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
|
En recrutement
|
07 mai 2025
|
|
NCT06486441
|
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy
|
En recrutement
|
06 mai 2025
|
|
NCT06781983
|
A Phase 1, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of IPH4502 as a Single Agent in Advanced Solid Tumors
|
En recrutement
|
04 mai 2025
|
|
NCT06669117
|
A First-In-Human (FIH) Phase I/II Open-label, Multicentre, Dose Escalation and Expansion Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors Including Non-small Cell Lung Cancer (NSCLC) Harboring Mesenchymal-Epithelial Transition (MET) Alterations
|
En recrutement
|
04 mai 2025
|
|
NCT05732831
|
A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG462 as a Single Agent and in Combination in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors
|
En recrutement
|
03 mai 2025
|
|
NCT06864169
|
A Phase 2 Nonrandomized, Open-label, Multisite Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan in Participants With Gastrointestinal Cancers
|
En recrutement
|
01 mai 2025
|
|
NCT06492616
|
Elacestrant Versus Standard Endocrine Therapy in Women and Men With Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer With High Risk of Recurrence-A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)
|
En recrutement
|
29 avril 2025
|
|
NCT05685173
|
A Phase 1 Study to Assess Safety and Tolerability of REGN5837, an Anti-CD22 x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody, in Combination With Odronextamab, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients With Aggressive B-Cell Non-Hodgkin Lymphomas (ATHENA-1)
|
En recrutement
|
29 avril 2025
|
|
NCT05537740
|
First-in-human Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the Anti-CCR8 Antibody BAY 3375968 as Monotherapy and in Combination With Pembrolizumab in Participants With Selected Advanced Solid Tumors
|
En recrutement
|
25 avril 2025
|
|
NCT06333951
|
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)
|
En recrutement
|
25 avril 2025
|
|
NCT06091254
|
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X Anti-CD3 Bispecific Antibody Versus Investigator's Choice in Previously Untreated Participants With Follicular Lymphoma (OLYMPIA-1)
|
En recrutement
|
25 avril 2025
|
|
NCT06238479
|
A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Recurrent, Advanced or Metastatic Solid Tumors
|
En recrutement
|
23 avril 2025
|
|
NCT06413706
|
A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Temozolomide Compared to Temozolomide Monotherapy in Children and Young Adults With Newly Diagnosed High-Grade Glioma Following Radiotherapy
|
En recrutement
|
19 avril 2025
|
|
NCT05503797
|
A Phase 2 Master Protocol to Assess the Efficacy and Safety of FORE8394, an Inhibitor of BRAF Class 1 and Class 2 Alterations, in Participants With Cancer Harboring BRAF Alterations
|
En recrutement
|
18 avril 2025
|
|
NCT06297525
|
An Open-Label, Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics of the CTPS1 Inhibitor STP938 in Adult Subjects With Advanced Solid Tumors, With a Safety Expansion in Advanced CTPS2 Null Ovarian Cancer
|
En recrutement
|
16 avril 2025
|
|
NCT06064877
|
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN)
|
En recrutement
|
15 avril 2025
|
|
NCT06120283
|
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CDK4 Inhibitor BGB-43395, Alone or as Part of Combination Therapies in Patients With Metastatic HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
|
En recrutement
|
15 avril 2025
|
|
NCT06924099
|
Tumor Treating Fields General Routine Clinical Care in Newly Diagnosed Glioblastoma Patients: a French Prospective Non-Interventional Study - TIGER France
|
En recrutement
|
12 avril 2025
|
|
NCT04274868
|
Constitution of a Centralized Biological Resources Collection and Associated With a Clinical Database for Childhood Liver Tumors Diagnosed in France (Retrospective Collection From 1990 and Prospective)
|
En recrutement
|
12 avril 2025
|
|
NCT04031677
|
A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients With High Risk RetroPeritoneal Sarcoma (RPS)
|
En recrutement
|
11 avril 2025
|
|
NCT05206357
|
A Single Arm, Open-Label, Phase 1b Trial of Epcoritamab in Pediatric Patients With Relapsed/Refractory Aggressive Mature B-cell Neoplasms
|
En recrutement
|
05 avril 2025
|
|
NCT05973773
|
Randomized, Controlled, Open-label, Phase 3, Global Multi - Center Trial to Assess the Efficacy and Safety of Zipalertinib Plus Chemotherapy Versus Chemotherapy Alone, in Patients With Previously Untreated, Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations (REZILIENT3)
|
En recrutement
|
03 avril 2025
|
|
NCT06662786
|
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
|
En recrutement
|
01 avril 2025
|
|
NCT06524583
|
Interest of Adjuvant Chemotherapy in Patients With CINSARC High-risk Localized Resected Uterine Leiomyosarcoma - Sarcome 15 (L-UteCIN)
|
En recrutement
|
01 avril 2025
|
|
NCT06330064
|
A Phase 1B/2 Pan-Tumor, Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
|
En recrutement
|
27 mars 2025
|
|
NCT06150027
|
A Randomized Comparative Prospective Multicenter Study of the Efficacy of a Systematic Referral to Palliative Care of Patients Who Need for Palliative Care During an Unscheduled Visit in Comprehensive Anticancer Centers (PALLU)
|
En recrutement
|
18 mars 2025
|
|
NCT03820830
|
A Phase III Open-label, Multicenter, Randomized Trial of Adjuvant Palbociclib in Combination With Endocrine Therapy Versus Endocrine Therapy Alone for Patients With Hormone Receptor Positive / HER2-negative Resected Isolated Locoregional Recurrence of Breast Cancer
|
En recrutement
|
08 mars 2025
|
|
NCT06581432
|
Beamion PANTUMOR-1: A Phase II, Multicentre, Multicohort, Open-label Trial to Evaluate the Efficacy and Safety of Oral Zongertinib (BI 1810631) for the Treatment of Selected HER2-mutated or Overexpressed/Amplified Solid Tumours
|
En recrutement
|
07 mars 2025
|
|
NCT04526782
|
A Phase II Study of the BRAF Inhibitor Encorafenib in Combination With the MEK Inhibitor Binimetinib in Patients With BRAFV600E-mutant Metastatic Non-small Cell Lung Cancer
|
En recrutement
|
07 mars 2025
|
|
NCT04420884
|
An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors
|
En recrutement
|
01 mars 2025
|
|
NCT05828511
|
Phase 1/2 Study of Linvoseltamab (Anti-BCMA X Anti-CD3 Bispecific Antibody) in Previously Untreated Patients With Symptomatic Multiple Myeloma
|
En recrutement
|
22 février 2025
|
|
NCT06385080
|
A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
|
En recrutement
|
21 février 2025
|
|
NCT05029882
|
A Phase 1 First in Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-400 as Monotherapy and in Combination With Bevacizumab in Adult Subjects With Advanced Solid Tumors
|
En recrutement
|
21 février 2025
|
|
NCT06395103
|
LIGHTBEAM-U01 Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors
|
En recrutement
|
19 février 2025
|
|
NCT06415266
|
Multicentric Randomized Study eValuating the sExual Quality of Life in Breast Cancer Patients Receiving oncoSexology Supportive Care on Proactive Versus On-request (VENUS)
|
En recrutement
|
13 février 2025
|
|
NCT06813573
|
Prospective Analysis of Circulating Nucleosomes in Patients Receiving a First Line Treatment for a Non-Hodgkin Lymphoma
|
En recrutement
|
08 février 2025
|
|
NCT06319820
|
A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations (MoonRISe-1)
|
En recrutement
|
06 février 2025
|
|
NCT04892173
|
A Phase 3 Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination With Cetuximab for Platinum-based Chemotherapy-Ineligible Elderly Patients With LA-HNSCC
|
En recrutement
|
31 janvier 2025
|
|
NCT04423029
|
A Phase 1/1b, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monotherapy and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications
|
En recrutement
|
31 janvier 2025
|
|
NCT06172478
|
HERTHENA-PanTumor01 (U31402-277): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors
|
En recrutement
|
28 janvier 2025
|
|
NCT06475352
|
Dihydropyrimidine Dehydrogenase (DPD) Phenotype-guided Dose Individualization of Fluoropyrimidine-based Chemotherapy in DPD Deficient Patients With Gastrointestinal Cancers (FUDOSE)
|
En recrutement
|
28 janvier 2025
|
|
NCT06151574
|
Beamion LUNG 2: A Phase III, Open-label, Randomized, Active-controlled, Multi-centre Trial Evaluating Orally Administered Zongertinib (BI 1810631) Compared With Standard of Care as First-line Treatment in Patients With Unresectable, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Harbouring HER2 Tyrosine Kinase Domain Mutations
|
En recrutement
|
28 janvier 2025
|
|
NCT05489237
|
A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) [Study ID: StrateGIST 1]
|
En recrutement
|
18 janvier 2025
|
|
NCT05153239
|
A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination With Irinotecan Versus Investigator's Choice (Topotecan or Irinotecan) in Relapsed Small Cell Lung Cancer Patients (LAGOON Trial)
|
En recrutement
|
17 janvier 2025
|
|
NCT04044768
|
A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T Cells in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
|
En recrutement
|
14 janvier 2025
|
|
NCT02813135
|
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
|
En recrutement
|
11 janvier 2025
|
|
NCT05688280
|
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors. A Multicenter Phase 1b/2a Trial in Colorectal Cancer, Non-small Cell Lung Cancer, and Soft Tissue Sarcoma Patients (INJECTABL-1)
|
En recrutement
|
09 janvier 2025
|
|
NCT04529122
|
A Registry to Collect Characteristics and Outcomes From Patients With Solid Tumors Profiled With a Next-Generation Sequencing Test (WAYFIND-R)
|
En recrutement
|
08 janvier 2025
|
|
NCT05238922
|
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy and in Combination With Anticancer Therapies in Participants With Selected Advanced Solid Tumors
|
En recrutement
|
28 décembre 2024
|
|
NCT06435429
|
A Phase 3, Randomized, Open-label, Multicenter, Controlled Study to Evaluate the Efficacy and Safety of Zanidatamab in Combination With Physician's Choice Chemotherapy Compared to Trastuzumab in Combination With Physician's Choice Chemotherapy for the Treatment of Participants With Metastatic HER2-positive Breast Cancer Who Have Progressed on, or Are Intolerant to, Previous Trastuzumab Deruxtecan Treatment
|
En recrutement
|
28 décembre 2024
|
|
NCT06225596
|
A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
|
En recrutement
|
21 décembre 2024
|
|
NCT05830084
|
Phase Ib Study of the Combination of Regorafenib With Conventional Chemotherapy for the Treatment of Newly Diagnosed Patients With Multimetastatic Ewing Sarcoma
|
En recrutement
|
20 décembre 2024
|
|
NCT05601752
|
A Phase 2, Open-Label, Randomized, Non-Comparative Clinical Trial of ADP-A2M4CD8 Monotherapy and in Combination with Nivolumab in Subjects with Recurrent Ovarian Cancers
|
En recrutement
|
20 décembre 2024
|
|
NCT06346067
|
A Randomized, Open-label Phase III Study in Patients With Previously Treated Unresectable or Metastatic NRAS Mutant Cutaneous Melanoma Comparing the Combination of Naporafenib + Trametinib to Physician's Choice of Therapy (Dacarbazine, Temozolomide or Trametinib Monotherapy) With a Dose Optimization lead-in [SEACRAFT-2]
|
En recrutement
|
19 décembre 2024
|
|
NCT03609112
|
Neurocognitive Risks in Children With Solid Tumors
|
En recrutement
|
14 décembre 2024
|
|
NCT05874063
|
Thromboprophylaxis in Good and Intermediate Prognosis Advanced Germ Cell Tumors
|
En recrutement
|
14 décembre 2024
|
|
NCT03715933
|
An Open-Label, Multicenter, First-in-Human, Phase 1 Dose-Escalation and Multicohort Expansion Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas
|
En recrutement
|
13 décembre 2024
|
|
NCT04811560
|
A Phase 1/2, First-in-Human Study of the Menin-KMT2A (MLL1) Inhibitor Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
|
En recrutement
|
11 décembre 2024
|
|
NCT03742895
|
A Phase 2 Study of Olaparib Monotherapy in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer
|
En recrutement
|
10 décembre 2024
|
|
NCT05512377
|
Brightline-2: A Phase IIa/IIb, Open-label, Single-arm, Multi-centre Trial of BI 907828 (Brigimadlin) for Treatment of Patients With Locally Advanced / Metastatic, MDM2 Amplified, TP53 Wild-type Biliary Tract Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, or Other Selected Solid Tumours
|
En recrutement
|
06 décembre 2024
|
|
NCT05631249
|
An Interventional and Translational Study Investigating Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C
|
En recrutement
|
05 décembre 2024
|
|
NCT05753501
|
First-in-Human Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of the BTK Degrader, ABBV-101, in Participants With B-cell Malignancies
|
En recrutement
|
04 décembre 2024
|
|
NCT06078384
|
Adjuvant Pembrolizumab and Chemotherapy or Surveillance in Early Triple Negative breAst Cancer With High Stromal Tumor-infiltrating Lymphocytes (TILs) Score
|
En recrutement
|
04 décembre 2024
|
|
NCT05491317
|
A Phase 1 Dose Finding and Phase 2, Randomized, Open-Label Trial to Evaluate the Safety and Clinical Activity of Immunoradiotherapy Combinations as a Treatment Option in Subjects With Metastatic Solid Tumors
|
En recrutement
|
04 décembre 2024
|
|
NCT06712472
|
Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for P53abn Endometrial Cancer
|
En recrutement
|
03 décembre 2024
|
|
NCT04713514
|
Randomized Phase II Study Comparing Neo-epitope Based Vaccine OSE2101 (TEDOPI®) With or Without Anti-PD1 (Pembrolizumab) Versus Best Supportive Care as Maintenance Treatment in Platinum-sensitive Recurrent Ovarian Cancer Patient With Controlled Disease After Platinum-based Chemotherapy
|
En recrutement
|
03 décembre 2024
|
|
NCT05909904
|
A Randomized, Phase 2, Open-Label, Multi-Arm Study of Tislelizumab in Combination With Investigational Agents as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
|
En recrutement
|
28 novembre 2024
|
|
NCT06276465
|
Combination of Darolutamide and Stereotactic Body Radiation Therapy in Patients With Castration Resistant Prostate Cancer and Oligometastases on Functional Imaging
|
En recrutement
|
27 novembre 2024
|
|
NCT05111626
|
A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression
|
En recrutement
|
23 novembre 2024
|
|
NCT06211257
|
Phase 3 Superiority Trial Evaluating the Benefit of Dematerialized Information Media for Patients with Advanced Sarcomas Receiving Second Line Treatment.
|
En recrutement
|
21 novembre 2024
|
|
NCT03878342
|
Prospective Study of Omission of Whole-breast Radiotherapy Following Breast-conserving Surgery in Patients With Very Low Risk Ductal Carcinoma in Situ of the Breast
|
En recrutement
|
16 novembre 2024
|
|
NCT05645692
|
A Phase II, Randomized, Multicenter, Open-Label, Controlled Study of Tobemstomig Alone or in Combination With Tiragolumab Versus Atezolizumab in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer Who Are Ineligible for Platinum-Containing Chemotherapy
|
En recrutement
|
14 novembre 2024
|
|
NCT06360354
|
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 in Combination With Other Therapies in Subjects With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous MTAP-deletion
|
En recrutement
|
09 novembre 2024
|
|
NCT05275478
|
A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG908 in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors
|
En recrutement
|
09 novembre 2024
|
|
NCT04224389
|
Prospective Non-randomized Comparative Study Between IMRT and Primary Transoral Surgery in the Treatment of Squamous Cell Carcinomas of Early Local Stage of Oropharynx
|
En recrutement
|
09 novembre 2024
|
|
NCT06660147
|
PAOLA-1 Ancillary Study: Retrospective Validation of KELIM as a Predictive and Prognostic Factor for Maintenance Treatment With PARP Inhibitor After Platinum-Based Chemotherapy in First-Line Ovarian Cancer (KELI-PAOLA)
|
En recrutement
|
29 octobre 2024
|
|
NCT05592626
|
A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule, in Subjects With Unresectable, Locally Advanced, or Metastatic Solid Tumors That Are Antigen-rich (START-001)
|
En recrutement
|
25 octobre 2024
|
|
NCT04704934
|
A Phase 3, Multicenter, 2-Arm Randomized, Open-Label Study of Trastuzumab Deruxtecan in Subjects With HER2-Positive Metastatic and/or Unresectable Gastric or Gastro-Esophageal Junction (GEJ) Adenocarcinoma Subjects Who Have Progressed on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
|
En recrutement
|
25 octobre 2024
|
|
NCT04077463
|
An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer
|
En recrutement
|
25 octobre 2024
|
|
NCT06311578
|
Phase 1 Study of Intratumoral Administration of JNJ-87704916, an Oncolytic Virus, as Monotherapy and in Combination for Advanced Solid Tumors
|
En recrutement
|
22 octobre 2024
|
|
NCT04652076
|
A Randomized, Multicenter, Open Label, Phase I/II Study to Evaluate the Safety, Clinical and Biological Activity of a Humanized Monoclonal Antibody Targeting Netrin-1 (NP137) in Combination with Carboplatin Plus Paclitaxel And/or Pembrolizumab in Patients with Locally Advanced/metastatic Endometrial Carcinoma or Cervix Carcinoma Progressing/relapsing After At Least One Prior Systemic Chemotherapy.
|
En recrutement
|
09 octobre 2024
|
|
NCT04924075
|
A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α Related Genetic Alterations
|
En recrutement
|
04 octobre 2024
|
|
NCT05599984
|
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination With Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects With Advanced Solid Tumors
|
En recrutement
|
25 septembre 2024
|
|
NCT04417465
|
A Phase 1, Multi-center, Open Label First-in-Human Study With ABBV-CLS-579 Alone and in Combination in Subjects With Locally Advanced or Metastatic Tumors
|
En recrutement
|
25 septembre 2024
|
|
NCT04773782
|
A Phase 1/2, Single-arm Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling
|
En recrutement
|
24 septembre 2024
|
|
NCT06239467
|
PIKture-01: First-in-Human Study of the PI3KαH1047R Mutant-Selective Inhibitor OKI-219 as Monotherapy in Participants With Advanced Solid Tumors and as Part of Combination Therapy in Participants With Advanced Breast Cancer
|
En recrutement
|
21 septembre 2024
|
|
NCT03839771
|
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy. (HOVON150AML)
|
En recrutement
|
21 septembre 2024
|
|
NCT03829462
|
A Randomized Phase III Trial Assessing a Regorafenib-irinotecan Combination (REGIRI) Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients After Failure of Standard Therapies, According to the A/A Genotype of Cyclin D1 (NEXT-REGIRI)
|
En recrutement
|
21 septembre 2024
|
|
NCT03774732
|
PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer
|
En recrutement
|
20 septembre 2024
|
|
NCT05382286
|
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1
|
En recrutement
|
20 septembre 2024
|
|
NCT05361395
|
A Phase 1b Study Evaluating the Safety and Efficacy of First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung (DeLLphi-303)
|
En recrutement
|
20 septembre 2024
|
|
NCT06131398
|
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 355 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
|
En recrutement
|
06 septembre 2024
|
|
NCT05307705
|
A Study of LOXO-783 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With Advanced Breast Cancer and Other Solid Tumors With a PIK3CA H1047R Mutation (PIKASSO-01)
|
En recrutement
|
05 septembre 2024
|
|
NCT04498767
|
Stereotactic Body Radiotherapy in Addition to Standard of Care Treatment in Patients With Rare Oligometastatic Cancers (OligoRARE): a Randomized, Phase 3, Open-label Trial
|
En recrutement
|
27 août 2024
|
|
NCT02089100
|
Multicentric Phase III Trial of Superiority of Stereotactic Body Radiation Therapy in Patients With Metastatic Breast Cancer in First-line Treatment
|
En recrutement
|
16 août 2024
|
|
NCT05481502
|
A Prospective Trial to Evaluate Immune Determinants of the Response and the Toxicity to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors
|
En recrutement
|
15 août 2024
|
|
NCT03656536
|
A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)
|
En recrutement
|
27 juillet 2024
|
|
NCT05888844
|
A Phase 2 Study Evaluating INCB099280 in Participants With Advanced Squamous Cell Carcinoma
|
En recrutement
|
27 juillet 2024
|
|
NCT06511648
|
A Phase 2, Open-label, Multi-centre, Multi-national Interventional Trial to Evaluate the Efficacy and Safety of Erdafitinib (ERDA) Monotherapy and Erdafitinib (ERDA) and Cetrelimab (CET) Combination as Neoadjuvant Treatment in Cisplatin-ineligible Patients With Muscle-invasive Bladder Cancer (MIBC) Whose Tumours Express Fibroblast Growth Factor Receptor ( FGFR ) Gene Alterations
|
En recrutement
|
23 juillet 2024
|
|
NCT05918302
|
Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy with 177Lu-edotreotide Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.
|
En recrutement
|
23 juillet 2024
|
|
NCT03738267
|
Study on the Occurrence of Head and Neck Cancers During Pregnancy
|
En recrutement
|
18 juillet 2024
|
|
NCT03319940
|
A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Tarlatamab in Subjects With Small Cell Lung Cancer (DeLLphi-300)
|
En recrutement
|
17 juillet 2024
|
|
NCT06043817
|
First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
|
En recrutement
|
11 juillet 2024
|
|
NCT04216953
|
A Multicentre, Open-label, Phase I-II Study Evaluating the Combination of a MEK Inhibitor and a PDL1 Inhibitor in Pediatric and Adult Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma.
|
En recrutement
|
09 juillet 2024
|
|
NCT05280314
|
Phase II, Multi-cohort Trial of Neoadjuvant and Post-surgery IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Selected Resectable Tumors
|
En recrutement
|
01 juillet 2024
|
|
NCT04083599
|
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects With Malignant Solid Tumors
|
En recrutement
|
01 juillet 2024
|
|
NCT06295809
|
A Phase 2/3, Adaptive, Randomized, Open-label, Clinical Study to Evaluate Neoadjuvant and Adjuvant Intismeran Autogene (mRNA-4157) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care, and Pembrolizumab Monotherapy in Participants With Resectable Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (INTerpath-007)
|
En recrutement
|
01 juillet 2024
|
|
NCT05768139
|
First-in-Human Study of STX-478, a Mutant-Selective PI3Kα Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
|
En recrutement
|
29 juin 2024
|
|
NCT04932525
|
Gustave Roussy Cancer Profiling
|
En recrutement
|
29 juin 2024
|
|
NCT05180006
|
Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy
|
En recrutement
|
29 juin 2024
|
|
NCT06479057
|
Integrating PROACTive Care Pathways to Empower and Support Cancer Patients (PROACT)
|
En recrutement
|
29 juin 2024
|
|
NCT05983367
|
A Randomized Phase 2 Study of Ompenaclid Versus Placebo in Combination With FOLFIRI Plus Bevacizumab in Patients With Previously Treated RAS Mutant Advanced or Metastatic Colorectal Cancer
|
En recrutement
|
28 juin 2024
|
|
NCT04823403
|
A Phase I Study Evaluating Safety and Efficacy of Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma
|
En recrutement
|
28 juin 2024
|
|
NCT04660344
|
A Phase III, Double-Blind, Multicenter, Randomized Study of Atezolizumab (Anti-PDL1 Antibody) Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy
|
En recrutement
|
27 juin 2024
|
|
NCT05647122
|
A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumors
|
En recrutement
|
25 juin 2024
|
|
NCT05403554
|
A Phase 1, Open-Label, Dose Finding Study of NI-1801, a Bispecific Mesothelin X CD47 Engaging Antibody, As a Single Agent, in Combination with Anti-PD-1 Antibody, and in Combination with Weekly Paclitaxel (Standard of Care) in Patients with Mesothelin Expressing Ovarian, Pancreatic, Non-Small-Cell-Lung and Triple-Negative Breast Cancers
|
En recrutement
|
25 juin 2024
|
|
NCT05208762
|
A Phase 1 Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
|
En recrutement
|
24 juin 2024
|
|
NCT04725331
|
A Phase I/IIa Study of Intra-tumoral BT-001 (TG6030) Administered Alone and in Combination With Pembrolizumab in Patients With Cutaneous or, Subcutaneous Lesions or Easily Injectable Lymph Nodes of Metastatic/Advanced Solid Tumors.
|
En recrutement
|
22 juin 2024
|
|
NCT06095089
|
A Phase 1 Study of JNJ-87189401 (PSMA-CD28 Bispecific Antibody) Combined With JNJ-78278343 (KLK2-CD3 Bispecific Antibody) for Advanced Prostate Cancer
|
En recrutement
|
22 juin 2024
|
|
NCT05215106
|
Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva)
|
En recrutement
|
22 juin 2024
|
|
NCT04919811
|
A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients with Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors
|
En recrutement
|
21 juin 2024
|
|
NCT05855200
|
A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy Versus Standard of Care in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
|
En recrutement
|
21 juin 2024
|
|
NCT04742101
|
Phase I / II, Open Label, Dose Escalation Part (Phase I) Followed by Non-comparative Expansion Part (Phase II), Multi-centre Study, Evaluating Safety, Pharmacokinetics and Efficacy of S65487, a Bcl2 Inhibitor Combined With Azacitidine in Adult Patients With Previously Untreated Acute Myeloid Leukemia Not Eligible for Intensive Treatment
|
En recrutement
|
21 juin 2024
|
|
NCT05623397
|
QT on RIBociclib measuRed by ArTificial INteliGence
|
En recrutement
|
21 juin 2024
|
|
NCT05552001
|
ISIdE: Open Label, Multicentric, Single-arm Phase IIIB Trial to Evaluate the Safety and Efficacy of Sacituzumab Govitecan in Triple Negative Metastatic Breast Cancer Patients With a Biomarker Analysis
|
En recrutement
|
21 juin 2024
|
|
NCT04857372
|
An Open-label, Multi-center, Phase I Study of Oral IAG933 in Adult Patients With Advanced Mesothelioma and Other Solid Tumors
|
En recrutement
|
20 juin 2024
|
|
NCT02856425
|
Phase Ib Trial Of Pembrolizumab And Nintedanib
|
En recrutement
|
20 juin 2024
|
|
NCT01993498
|
A Prospective Cohort to Investigate Survivorship Issues in Patients With Early Cancer
|
En recrutement
|
20 juin 2024
|
|
NCT05501886
|
Phase 3, Open-Label, Randomized, Study Comparing Gedatolisib Combined With Fulvestrant & With or Without Palbociclib to Standard-of-Care Therapies in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination w/Non-Steroidal Aromatase Inhibitor Therapy
|
En recrutement
|
19 juin 2024
|
|
NCT06298084
|
Phase 1b/2, Multicenter, Open-label, Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd
|
En recrutement
|
19 juin 2024
|
|
NCT04985266
|
A Randomised Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer
|
En recrutement
|
19 juin 2024
|
|
NCT05629585
|
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (DatoDXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)
|
En recrutement
|
19 juin 2024
|
|
NCT05888831
|
A Phase 1/2 Study of BMS-986449 Alone and in Combination With Nivolumab in Participants With Advanced Solid Tumors
|
En recrutement
|
18 juin 2024
|
|
NCT05800964
|
Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors
|
En recrutement
|
18 juin 2024
|
|
NCT02628067
|
A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)
|
En recrutement
|
17 juin 2024
|
|
NCT05118789
|
A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors (ARROS-1)
|
En recrutement
|
15 juin 2024
|
|
NCT01566019
|
Molecular Screening Analysis Used as Decision Tool for Targeted Molecular Treatment
|
Statut inconnu
|
15 juin 2024
|
|
NCT05182164
|
Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas
|
En recrutement
|
15 juin 2024
|
|
NCT05152472
|
A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined with Atezolizumab Versus Imatinib Resumption Alone in Patients with Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments
|
En recrutement
|
15 juin 2024
|
|
NCT00127049
|
A Prospective Multicenter Phase II Trial of Gemcitabine, Cisplatin, and Ifosfamide (GIP) in Patients With Relapsed Non-Seminomatous Germ-Cell Tumors (NSGCT) and a Predicted Favorable Prognosis
|
Statut inconnu
|
15 juin 2024
|
|
NCT03474094
|
A European, Multicenter, Randomized, Open-label, Phase II Trial Aiming to Assess the Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy
|
Statut inconnu
|
15 juin 2024
|
|
NCT00126269
|
A Randomized Phase III Trial Comparing Cisplatin With or Without Gemcitabine in Patients With Carcinoma of Unknown Primary and a Predicted Favorable Prognosis
|
Statut inconnu
|
15 juin 2024
|
|
NCT04807816
|
Targeting ATR in Soft-tissue Sarcomas: a Randomized Phase II Study. TARSARC Study
|
En recrutement
|
15 juin 2024
|
|
NCT04925609
|
A Phase I/II Study of Brigatinib in Pediatric and Young Adult Patients With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors
|
En recrutement
|
15 juin 2024
|
|
NCT00349505
|
Phase II Study of Intra-Peritoneal Hyper-Thermic Chemotherapy as Consolidation Therapy for Advanced Epithelial Ovarian Carcinoma
|
Statut inconnu
|
15 juin 2024
|
|
NCT00162721
|
Phase III Study About the Effects of the Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas
|
Statut inconnu
|
15 juin 2024
|
|
NCT00181038
|
Analgesia of Fibula Free Flap Donor Site by Peri-Neuronal Catheter in Oro-Pharyngeal Carcinoma Surgery: Comparing Continuous Infusion of Local Anesthetic With Systemic Multimodal Analgesia
|
Statut inconnu
|
15 juin 2024
|
|
NCT05329792
|
A Phase II Study of L19IL2/L19TNF in Patients With Skin Cancers Amenable to Intralesional Treatment
|
En recrutement
|
15 juin 2024
|
|
NCT00180791
|
Treatment Protocol for High-Risk PNET Brain Tumors in Children With Surgery, Sequential Chemotherapy, Conventional and High-Dose With Peripheral Blood Stem Cell Transplantation and Radiation Therapy
|
Statut inconnu
|
15 juin 2024
|
|
NCT00935675
|
|
Statut inconnu
|
15 juin 2024
|
|
NCT00180882
|
|
Statut inconnu
|
15 juin 2024
|
|
NCT00162669
|
Phase II Study Evaluating the Efficacy of Bevacizumab (Avastin@) in Hepatocellular Carcinoma Not Amenable to Curative Treatment
|
Statut inconnu
|
15 juin 2024
|
|
NCT01167530
|
|
Statut inconnu
|
15 juin 2024
|
|
NCT05180825
|
A Randomized and Controlled Phase II Protocol in Non NF1 Pediatric and AYA (Adolescent and Young Adults) Patients Bearing a Newly Diagnosed Low Grade Glioma With Wild Type BRAF Gene Comparing a Daily Oral MEK Inhibitor (Trametinib) Versus Weekly Vinblastine for 18 Months
|
En recrutement
|
15 juin 2024
|
|
NCT02666612
|
Measurement and Characterization of Circulating Endothelial Cells or Circulating Tumor Cells or Circulating DNA in Adult Patients With Metastatic Cancer
|
Statut inconnu
|
15 juin 2024
|
|
NCT02115165
|
A Prospective Phase II Trial of Cabazitaxel in Male Patients With Chemotherapy Pre-treated Metastatic Nonseminomatous Germ-cell Tumors
|
Statut inconnu
|
15 juin 2024
|
|
NCT02679963
|
A Randomized Double-blind Phase II Trial Evaluating Maintenance Olaparib Versus Placebo in Patients With Platinum-sensitive Advanced Non-small Cell Lung Cancer
|
Statut inconnu
|
15 juin 2024
|
|
NCT03604588
|
Evaluation of HPV OncoTect ™ for the Etiological Diagnosis of HPV-induced Oropharyngeal Cancers (HPV OncoTect™)
|
Statut inconnu
|
15 juin 2024
|
|
NCT02828462
|
Impact of a Monitoring Device for Patients With Cancer Treated Using Oral Therapeutics
|
Statut inconnu
|
15 juin 2024
|
|
NCT03613194
|
Mechanistic and Molecular Study of the Process of Metastatic Dissemination in Colorectal Cancer
|
Statut inconnu
|
15 juin 2024
|
|
NCT03983369
|
Multicenter Double Blind Randomized Placebo-controlled Trial Assessing the Efficacy of Low-level Laser Therapy in the Prevention of Chemotherapy-induced Mucositis in Children and Young Adults (MUCILA)
|
En recrutement
|
15 juin 2024
|
|
NCT03155386
|
Evaluation of the Clinical Performance of Optimized Angiomammography and Comparison With Standard Angiomammography (OPTIAM)
|
Statut inconnu
|
15 juin 2024
|
|
NCT03606070
|
Multiparametric PET-MRI Integration for a New Approach to Tumor Heterogeneity in Non-Small Cell Lung Cancer (NSCLC): Pilot Study
|
Statut inconnu
|
15 juin 2024
|
|
NCT02215720
|
Phase I Study of Temsirolimus and Cetuximab in Adults Patients With Advanced or Metastatic Solid Tumors
|
Statut inconnu
|
15 juin 2024
|
|
NCT05384821
|
Phase 1-2 Trial Evaluating Metronomic Chemotherapy in Patients With a Relapsed or Refractory Wilms Tumor
|
En recrutement
|
15 juin 2024
|
|
NCT05096390
|
Multicenter Phase II Study of Axitinib +/- Pembrolizumab in First Line Treatment for Patients With Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (PRCC)
|
En recrutement
|
15 juin 2024
|
|
NCT01689584
|
Study of Family COsegregation of Nucleotide VARiants in the Panel of Genes to Validate Their Use in Genetic Counseling
|
En recrutement
|
15 juin 2024
|
|
NCT05168839
|
Intraoperative Indocyanine Green Fluorescence Angiography in Colorectal Surgery to Prevent Anastomotic Leakage: a Single-blind Phase III Multicenter Randomized Controlled Trial (Intergroup FRENCH-GRECCAR Trial)
|
En recrutement
|
15 juin 2024
|
|
NCT04341207
|
COVID 19 - Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease Upon Hydroxychloroquine and Azithromycin Therapy in French Cancer Patients
|
Statut inconnu
|
15 juin 2024
|
|
NCT04826445
|
USE OF 18FDG PET-CT TO PREDICT THE RESPONSE OF MANDIBULAR OSTEORADIONECROSIS TO THE PENTOCLO PROTOCOL WITH DOCUMENTED ANTIBIOTHERAPY (PENTOTEP)
|
Statut inconnu
|
15 juin 2024
|
|
NCT05071001
|
Long Term Brain Toxicity of Chemotherapy in Patients Treated for a Bone TumorDuring Childhood or Adolescence
|
Statut inconnu
|
15 juin 2024
|
|
NCT04731610
|
Randomized, Multicenter, Phase III Trial to Assess Conformal Post-operative Radiotherapy vs. Surveillance After Complete Resection of Stage II/III Thymoma
|
En recrutement
|
15 juin 2024
|
|
NCT06112314
|
A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301
|
En recrutement
|
15 juin 2024
|
|
NCT05794906
|
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Darolutamide Plus Androgen Deprivation Therapy (ADT) Compared With Placebo Plus ADT in Patients With High-risk Biochemical Recurrence (BCR) of Prostate Cancer
|
En recrutement
|
15 juin 2024
|
|
NCT04597125
|
A Phase 4, Randomized, Open-label, Multicenter Efficacy and Safety Study of Standard Dose of Radium-223 Dichloride vs. Standard Doses of Novel Anti-hormonal Therapy (NAH) in Patients With Bone Dominant Metastatic Castration Resistant Prostate Cancer (mCRPC) Progressing on/After One Line of NAH
|
En recrutement
|
15 juin 2024
|
|
NCT02265770
|
An International Clinical Program for the Diagnosis and Treatment of Children, Adolescents and Young Adults With Ependymoma
|
En recrutement
|
15 juin 2024
|
|
NCT04095208
|
Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II Study.
|
En recrutement
|
15 juin 2024
|
|
NCT03624244
|
Randomized Comparative Prospective Multicentre Phase II Trial Evaluating Clinical Impact of Interruption VS Maintenance of AI in Patients with Locally Advanced/ Metastatic LGESS
|
En recrutement
|
15 juin 2024
|
|
NCT04176198
|
A Phase 1/2, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral Nuvisertib (TP-3654) in Patients With Intermediate or High-Risk Primary or Secondary Myelofibrosis
|
En recrutement
|
15 juin 2024
|
|
NCT06174987
|
A Master Rollover Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
|
En recrutement
|
15 juin 2024
|
|
NCT03767075
|
Basket of Baskets: A Modular, Open-label, Phase II, Multicentre Study To Evaluate Targeted Agents in Molecularly Selected Populations With Advanced Solid Tumours (BoB)
|
En recrutement
|
15 juin 2024
|
|
NCT03547973
|
A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
|
En recrutement
|
15 juin 2024
|
|
NCT03475953
|
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
|
En recrutement
|
15 juin 2024
|
|
NCT03964233
|
A Phase Ia/Ib, Open Label, Dose-escalation Study of the Combination of BI 907828 (Brigimadlin) With BI 754091 (Ezabenlimab) and BI 754111 and the Combination of BI 907828 (Brigimadlin) With BI 754091(Ezabenlimab) Followed by Expansion Cohorts, in Patients With Advanced Solid Tumors
|
En recrutement
|
15 juin 2024
|
|
NCT03819101
|
A Phase III Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer
|
En recrutement
|
15 juin 2024
|
|
NCT03570021
|
ESTIMation of the ABiLity of Prophylactic Central Compartment Neck Dissection to Modify Outcomes in Low-risk Differentiated Thyroid Cancer
|
En recrutement
|
15 juin 2024
|
|
NCT05912075
|
An Open-Label Multicenter Phase 1b Study of Tolinapant (ASTX660) in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Patients With Rectum Cancer (PRAAR 1: Preoperative Radiotherapy And ASTX660 in Rectum Cancer)
|
En recrutement
|
15 juin 2024
|
|
NCT03406247
|
Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma : Phase 2 Trial Evaluating the Efficacy and the Toxicity of Nivolumab Alone, and of the Combination Nivolumab and Ipilimumab
|
En recrutement
|
15 juin 2024
|
|
NCT04477681
|
Securing Access to Innovative Molecules in Oncology and Hematology for Children, Adolescents and Young Adults in Therapeutic Failure or Relapse and Not Eligible for a Clinical Trial: a Project of the SFCE
|
En recrutement
|
15 juin 2024
|
|
NCT05076396
|
Phase I, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM14 Administered Intravenously to Patients with Advanced Solid Tumors
|
En recrutement
|
15 juin 2024
|
|
NCT05890781
|
Engineering Immune Organoids to Study Pediatric Cancer (IMMUNE-ORGANOIDS)
|
En recrutement
|
15 juin 2024
|
|
NCT05889585
|
Morbidity, Long-term Side Effects and Quality of Life in Germ-cell Tumor Long Survivors Treated with High-dose Chemotherapy and Autologous Stem Cell Transplant
|
En recrutement
|
15 juin 2024
|
|
NCT05137054
|
Phase 1b Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Cancer Treatments for Patients With Relapsed/Refractory Multiple Myeloma
|
En recrutement
|
15 juin 2024
|
|
NCT04950075
|
A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma
|
En recrutement
|
15 juin 2024
|
|
NCT06364631
|
First Line Randomised Study Platform to Optimize Treatment in Patients With Metastatic Renal Cell Carcinoma
|
En recrutement
|
15 juin 2024
|
|
NCT06065748
|
A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy
|
En recrutement
|
15 juin 2024
|
|
NCT04702581
|
A Randomized Trial of Delayed Radiotherapy in Patients 1p/19q Codeleted Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery
|
En recrutement
|
15 juin 2024
|
|
NCT05625087
|
A ctDNA Screening Program in Patients With HR+, HER2- Metastatic Breast Cancer for Detection of High-risk Relapse Patients on Any CDK4/6 Inhibitor and a Randomised Phase II Study Comparing Alpelisib Combined With Fulvestrant to Ribociclib Combined With Fulvestrant, in Patients With Persistent Targetable PIK3CA Mutations
|
En recrutement
|
15 juin 2024
|
|
NCT04104776
|
A Phase 1/2 Study of DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
|
En recrutement
|
15 juin 2024
|
|
NCT05216432
|
A First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, As a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer
|
En recrutement
|
15 juin 2024
|
|
NCT05920356
|
A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202)
|
En recrutement
|
15 juin 2024
|
|
NCT05566795
|
LOGGIC/FIREFLY-2: A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients With Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy
|
En recrutement
|
15 juin 2024
|
|
NCT06045806
|
A Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9)
|
En recrutement
|
15 juin 2024
|
|
NCT04221035
|
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) (HR-NBL2)
|
En recrutement
|
15 juin 2024
|
|
NCT04567446
|
Discovery of Microbiome-based Biomarkers for Patients With Cancer Using Metagenomic
|
En recrutement
|
15 juin 2024
|
|
NCT05705687
|
A Prospective Program Aiming at Improving Outcome for Young Adults With Poor-prognosis
|
En recrutement
|
15 juin 2024
|
|
NCT05805501
|
A Randomized Open Label Phase II Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
|
En recrutement
|
14 juin 2024
|
|
NCT05639751
|
A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT3789 as Monotherapy and in Combination With Docetaxel in Participants With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
|
En recrutement
|
12 juin 2024
|
|
NCT06090539
|
A Phase 1/2, Multi-Center, Open-Label, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BMS-986458, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed/Refractory Non-Hodgkin Lymphomas (R/R NHL)
|
En recrutement
|
12 juin 2024
|
|
NCT05884398
|
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide With Continued Versus Intermittent Androgen-Deprivation Therapy (ADT) Following PSA Response in Participants With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
|
En recrutement
|
12 juin 2024
|
|
NCT06178614
|
A Phase 1 Study of JNJ-87890387, an Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 3 (ENPP3) x CD3 Bispecific Antibody, for Advanced Solid Tumors
|
En recrutement
|
12 juin 2024
|
|
NCT06016920
|
A Phase 1/2a, Open-label, Dose-finding Trial to Evaluate Safety, Immunogenicity, and Anti-tumor Activity of VB10.16 and Pembrolizumab in Patients with Unresectable Recurrent or Metastatic HPV16-positive Head-Neck Squamous Cell Carcinoma
|
En recrutement
|
11 juin 2024
|
|
NCT03485209
|
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors
|
En recrutement
|
11 juin 2024
|
|
NCT03435796
|
Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells
|
En recrutement
|
10 juin 2024
|
|
NCT05176483
|
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors
|
En recrutement
|
10 juin 2024
|
|
NCT06284122
|
A Phase III Randomized, Open-label, International, Multicenter Study Evaluating the Efficacy and Safety of Mosunetuzumab Plus Lenalidomide in Comparison to Anti-CD20 Monoclonal Antibody Plus Chemotherapy in Subjects With Previously Untreated FLIPI 2-5 Follicular Lymphoma
|
En recrutement
|
10 juin 2024
|
|
NCT05210413
|
Spartalizumab and Low-dose PAzopanib in Refractory or Relapsed Solid TumOrs of Pediatric and Adults
|
En recrutement
|
10 juin 2024
|
|
NCT04626479
|
A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants With RCC (U03): Substudy 03A in First Line Metastatic Participants
|
En recrutement
|
10 juin 2024
|
|
NCT04842162
|
Study Evaluating Near-infrared Imaging Coupled With Indocyanine Green for Intraoperative Control of Resection Margins in ENT Surgery
|
En recrutement
|
10 juin 2024
|
|
NCT05299294
|
Observational Study of the Use of 8% Capsaicin Patch in Children 0 to 18 Years
|
En recrutement
|
10 juin 2024
|
|
NCT05608291
|
A Phase 3 Trial of Fianlimab (Anti-LAG-3) and Cemiplimab Versus Pembrolizumab in the Adjuvant Setting in Patients With Completely Resected High-risk Melanoma
|
En recrutement
|
06 juin 2024
|
|
NCT04224064
|
Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas
|
En recrutement
|
06 juin 2024
|
|
NCT04065399
|
A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients With Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or Nucleophosmin 1 (NPM1) Mutation
|
En recrutement
|
05 juin 2024
|
|
NCT02416388
|
Phase II/III Randomized Study to Improve Overall Survival in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus Mycophenolate Mofetil Prophylaxis of Graft Versus Host Disease in Allografted Patients in First CR : a Backbone InterGroup-1 Trial
|
En recrutement
|
05 juin 2024
|
|
NCT02233049
|
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication
|
En recrutement
|
05 juin 2024
|
|
NCT04008797
|
An Open-label Study of E7386 in Combination With Other Anticancer Drug(s) in Subjects With Solid Tumors
|
En recrutement
|
05 juin 2024
|
|
NCT05260528
|
An ALFA 2101 Multicenter Randomized Phase II Study: CPX-351 Versus Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics
|
En recrutement
|
05 juin 2024
|
|
NCT03768063
|
An Open Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B)
|
En recrutement
|
05 juin 2024
|
|
NCT02861573
|
Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)
|
En recrutement
|
04 juin 2024
|
|
NCT05855811
|
A Multicenter, Open-label, Randomized Phase II Study Aiming to Assess the Clinical Impact of Dostarlimab on Occurrence of Second Primary Cancer in Patients With Cured Primary Cancer (PREDOSTAR)
|
En recrutement
|
04 juin 2024
|
|
NCT05317416
|
A RANDOMIZED, 2-ARM, PHASE 3 STUDY OF ELRANATAMAB (PF-06863135) VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEM-CELL TRANSPLANTATION
|
En recrutement
|
03 juin 2024
|
|
NCT03175224
|
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
En recrutement
|
31 mai 2024
|
|
NCT02715284
|
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
|
En recrutement
|
31 mai 2024
|
|
NCT06007092
|
Multicentric Randomized Phase I/IIa Trial of the Safety and Immunogenicity of a Therapeutic Anti-HPV DC Targeting Vaccine in Patients With Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer
|
En recrutement
|
31 mai 2024
|
|
NCT02332668
|
A Phase I/II Study of Pembrolizumab (MK-3475) in Children With Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma (KEYNOTE-051)
|
En recrutement
|
31 mai 2024
|
|
NCT05498428
|
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced or Metastatic Solid Tumors Including EGFR-mutated Non-Small Cell Lung Cancer
|
En recrutement
|
31 mai 2024
|
|
NCT02517281
|
Prospective Clinical and Biologic Study of Secondary Cutaneous Effects in Targeted Cancer Therapies
|
En recrutement
|
31 mai 2024
|
|
NCT05463263
|
An Open-Label, First in Human, Phase 1/2 to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of the CTPS1 Inhibitor STP938 In Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas
|
En recrutement
|
31 mai 2024
|
|
NCT04589845
|
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial
|
En recrutement
|
31 mai 2024
|
|
NCT05607550
|
A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
|
En recrutement
|
30 mai 2024
|
|
NCT04725396
|
A Randomized Prospective Multicenter Study Comparing Fibula Free-flap Mandibular Reconstruction With or Without Preoperative Virtual Planning in Patients With Oral or Oropharyngeal Cancer
|
En recrutement
|
30 mai 2024
|
|
NCT03899155
|
Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies
|
En recrutement
|
29 mai 2024
|
|
NCT04886804
|
Beamion LUNG-1: An Open Label, Phase I Dose Escalation Trial, With Dose Confirmation and Expansion, of Zongertinib (BI 1810631) as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 Aberrations
|
En recrutement
|
29 mai 2024
|
|
NCT03010124
|
Prognostic and Predictive Biomarkers in Ovarian Cancers
|
En recrutement
|
29 mai 2024
|
|
NCT05549297
|
Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination With Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-positive Participants With Previously Treated Advanced Melanoma (TEBE-AM)
|
En recrutement
|
29 mai 2024
|
|
NCT04428554
|
Consolidative Radiotherapy for Metastatic Urothelial Bladder Cancer Patients Without Progression and With no More Than Three Residual Metastatic Lesions Following First Line Systemic Therapy: a Prospective Randomized Comparative Phase II Trial
|
En recrutement
|
28 mai 2024
|
|
NCT05348577
|
A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
|
En recrutement
|
28 mai 2024
|
|
NCT05407675
|
A Phase 1/2 Study of BMS-986408 Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors
|
En recrutement
|
28 mai 2024
|
|
NCT05325866
|
A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors With FGFR2b Overexpression (FORTITUDE-301)
|
En recrutement
|
27 mai 2024
|
|
NCT05198804
|
A Phase 1/2 Dose-Escalation and Dose-Expansion Study of ZN-c3 in Combination With Niraparib and ZN-c3 Monotherapy in Subjects With Platinum-Resistant Ovarian Cancer
|
En recrutement
|
27 mai 2024
|
|
NCT03833167
|
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants With High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630)
|
En recrutement
|
25 mai 2024
|
|
NCT03486873
|
A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants Who Are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab
|
En recrutement
|
25 mai 2024
|
|
NCT05625399
|
A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination Versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants With Previously Untreated Metastatic or Unresectable Melanoma
|
En recrutement
|
25 mai 2024
|
|
NCT05514028
|
Evaluation of Salivary RNAs in the Presence of an Adnexal Mass of Ovarian Origin - OVAmiARN Study
|
En recrutement
|
25 mai 2024
|
|
NCT05255653
|
Refining Adjuvant Treatment in Endometrial Cancer Based on Molecular Features: the P53abn-RED Trial, the MMRd-GREEN Trial, the NSMP-ORANGE Trial and the POLEmut-BLUE Trial
|
En recrutement
|
25 mai 2024
|
|
NCT05691608
|
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
|
En recrutement
|
23 mai 2024
|
|
NCT04005820
|
Treatment for French Pediatric Patients With Renal Tumours According to the International SIOP Renal Tumour Study Group (RTSG) 2016 UMBRELLA Protocol Including Analysis of Tumour Chromosome 1q Gain and Central Radiology Review
|
En recrutement
|
23 mai 2024
|
|
NCT04916613
|
A Double-blind Randomised Phase III Trial Evaluating the Efficacy of ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability and Not Elected for Docetaxel or Androgen Receptor Targeted Agents
|
En recrutement
|
23 mai 2024
|
|
NCT04913285
|
A Phase 1/1b Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-2787 in Participants With BRAF and/or NRAS Mutation-positive Solid Tumors.
|
En recrutement
|
17 mai 2024
|
|
NCT02074839
|
A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
|
En recrutement
|
17 mai 2024
|
|
NCT05650879
|
A Phase 1a/1b Study of ELVN-002 for the Treatment of Patients With HER2 Mutant Non-Small Cell Lung Cancer
|
En recrutement
|
17 mai 2024
|
|
NCT04699188
|
A Phase Ib/II Open-label, Multi-center Dose Escalation Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
|
En recrutement
|
17 mai 2024
|
|
NCT03930953
|
A Phase 1/2, Multi-center, Open-label Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule, CC-99282, Alone and in Combination With Anti-Lymphoma Agents in Subjects With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL).
|
En recrutement
|
17 mai 2024
|
|
NCT04064359
|
A Phase I, Open-label, Dose Finding Study to Assess the Safety, Tolerability, PK, and Preliminary Efficacy of OBT076, a CD205-directed ADC, in Recurrent and/or Metastatic CD205+ Solid Tumors
|
En recrutement
|
17 mai 2024
|
|
NCT04262466
|
Phase 1/2 Study of IMC-F106C in Advance PRAME-Positive Cancers
|
En recrutement
|
17 mai 2024
|
|
NCT02834884
|
SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
|
En recrutement
|
10 mai 2024
|
|
NCT02684708
|
European Network-Paediatric Hodgkin Lymphoma Study Group (EuroNet-PHL) Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents
|
En recrutement
|
07 mai 2024
|
|
NCT05094336
|
A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors
|
En recrutement
|
29 avril 2024
|
|
NCT04881032
|
Phase I/II Study of AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma (NANO-GBM)
|
En recrutement
|
29 avril 2024
|
|
NCT03816163
|
A Phase 2, Open-Label, Randomized Study to Assess the Efficacy and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma
|
En recrutement
|
26 avril 2024
|
|
NCT05665348
|
Randomised, Open-label, Phase II-III Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy
|
En recrutement
|
26 avril 2024
|
|
NCT04650984
|
A Phase III Study Comparing the Efficacy of the Combination of Doxorubicin and the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF to Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma
|
En recrutement
|
26 avril 2024
|
|
NCT05933577
|
A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma (INTerpath-001)
|
En recrutement
|
25 avril 2024
|
|
NCT03576417
|
A Phase III Randomized Trial of Post-operative Adjuvant Nivolumab and Concomitant Chemo-radiotherapy in High-risk Patients With Resected Squamous Cell Carcinoma of Head and Neck
|
En recrutement
|
16 avril 2024
|
|
NCT04188145
|
A Randomized Phase III Study Comparing Maintenance Treatment With Fluoropyrimidine + Bevacizumab Versus Fluoropyrimidine After Induction Chemotherapy for a Metastatic Colorectal Cancer
|
En recrutement
|
16 avril 2024
|
|
NCT04284969
|
Prehabilitation & Rehabilitation in Oncogeriatrics: Adaptation to Deconditioning Risk and Accompaniment of Patients' Trajectories-ovary/Elderly Women with Ovarian Cancer-2, a GINECO Multicenter Randomized Study (PROADAPT-ovary/EWOC-2)
|
En recrutement
|
16 avril 2024
|
|
NCT03364530
|
Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma: a Multicentric Single-arm Phase II Study (GEMOXIA-02)
|
En recrutement
|
16 avril 2024
|
|
NCT03732495
|
A Prospective, Multicentre Phase II Study of the Efficacy of Lenvatinib Combined With Denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid Carcinomas (LENVOS)
|
En recrutement
|
16 avril 2024
|
|
NCT02526095
|
National Oesophageal and Gastric Carcinomas Data Base Construction: the FREGAT (French EsoGastric Tumours) Data Base
|
En recrutement
|
16 avril 2024
|
|
NCT05568095
|
A Randomized, Open-Label, Multicenter Phase 3 Trial of Domvanalimab, Zimberelimab, and Chemotherapy Versus Nivolumab and Chemotherapy in Participants With Previously Untreated Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma (STAR-221)
|
En recrutement
|
11 avril 2024
|
|
NCT03830788
|
Erectile Dysfunction in Good Prognosis Prostate Cancer: a Phase III Medico-economic Study Comparing Brachytherapy to Stereotactic Body Radiotherapy (TEMPOS)
|
En recrutement
|
11 avril 2024
|
|
NCT02998385
|
A Phase III Randomized Study of Chemo-radiotherapy Versus Radiotherapy Alone in the Adjuvant Treatment of Salivary Glands and Nasal Tumors (IMRT or Protontherapy)
|
En recrutement
|
11 avril 2024
|
|
NCT02215265
|
A Phase III Trial of Risk-stratified, Reduced Intensity Adjuvant Treatment in Patients Undergoing Transoral Surgery for Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer
|
En recrutement
|
11 avril 2024
|
|
NCT05439005
|
Opioid Free Versus Opioid Based Anaesthesia for Free Flap Reconstruction Surgery of the Breast: A Phase III Multicentric Randomized Controlled Study.
|
En recrutement
|
10 avril 2024
|
|
NCT03703050
|
Phase II Trial of Nivolumab for Pediatric and Adult Relapsing/Refractory Anaplastic Large Cell Lymphoma, for Evaluation of Response in Patients With Progressive Disease Cohort 1 or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse Cohort 2
|
En recrutement
|
10 avril 2024
|
|
NCT02875548
|
Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study
|
En recrutement
|
10 avril 2024
|
|
NCT04120701
|
CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II
|
En recrutement
|
10 avril 2024
|
|
NCT05529251
|
Prospective Therapeutic De-escalation and miRNA-M371 Biomarker Evaluation Phase II Study for Stage IIa/IIb < 3 cm Seminomas (EDEN)
|
En recrutement
|
09 avril 2024
|
|
NCT03093116
|
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
|
En recrutement
|
08 avril 2024
|
|
NCT05208047
|
A Phase 3 Randomized, Open-Label, Multicenter Clinical Study of CGT9486+Sunitinib vs. Sunitinib in Subjects With Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors
|
En recrutement
|
08 avril 2024
|
|
NCT04300556
|
A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Subjects With Selected Tumor Types
|
En recrutement
|
02 avril 2024
|
|
NCT05052801
|
A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer With FGFR2b Overexpression
|
En recrutement
|
27 mars 2024
|
|
NCT04819100
|
LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC
|
En recrutement
|
23 mars 2024
|
|
NCT05908786
|
A Phase Ib/II, Open-Label, Multicenter, Randomized Platform Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma (MORPHEUS-NEO HCC)
|
En recrutement
|
23 mars 2024
|
|
NCT03096041
|
Phase 3 Study Randomized Against Placebo, Evaluating the Efficacy of Auriculotherapy in Patients With Musculoskeletal Pain by Aromatase Inhibitors in Adjuvant Treatment of Breast Cancer (TRIPLE-A)
|
En recrutement
|
20 mars 2024
|
|
NCT04790253
|
PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study)
|
En recrutement
|
18 mars 2024
|
|
NCT05221840
|
A Phase III, Double-blind, Placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy
|
En recrutement
|
18 mars 2024
|
|
NCT05450692
|
A Phase III, Open-label, Randomised, Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed On or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy: LATIFY (LATIFY)
|
En recrutement
|
18 mars 2024
|
|
NCT04116541
|
MegaMOST - a Multicenter, Open-label, Biology Driven, Phase II Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations /characteristics in Advanced / Metastatic Tumors. (MegaMOST)
|
En recrutement
|
18 mars 2024
|
|
NCT05692999
|
Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority Study (Pulse)
|
En recrutement
|
18 mars 2024
|
|
NCT05529979
|
Post-Market Clinical Follow-Up Study of a Robotic Device for Image Guided Percutaneous Needle Placement in the Abdomen
|
En recrutement
|
16 mars 2024
|
|
NCT04253015
|
A Post-Authorisation Safety Study Patient Registry of Patients With High-risk Neuroblastoma Being Treated With the Monoclonal Antibody Dinutuximab Beta
|
En recrutement
|
13 mars 2024
|
|
NCT05444712
|
Transplantation After Complete Response In Patients With T-cell Lymphoma
|
En recrutement
|
13 mars 2024
|
|
NCT02890095
|
Prospective, Multicenter, Epidemiological Case-control Study, to Establish a Possible Correlation Between Persistent Chemical Contaminants (POPs) and Breast Cancer.
|
En recrutement
|
08 mars 2024
|
|
NCT04522323
|
A Phase 1b, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI5752 in Combination With Axitinib in Subjects With Advanced Renal Cell Carcinoma
|
En recrutement
|
08 mars 2024
|
|
NCT03784014
|
Molecular Profiling of Advanced Soft-tissue Sarcomas. A Phase III Study
|
En recrutement
|
07 mars 2024
|
|
NCT04305054
|
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02B
|
En recrutement
|
06 mars 2024
|
|
NCT05155332
|
Phase I Open-label, Dose Escalation Trial of BI 1831169 Monotherapy and in Combination With an Anti-PD-1 mAb in Patients With Advanced or Metastatic Solid Tumors
|
En recrutement
|
02 mars 2024
|
|
NCT03313206
|
Phase II Multicentric Study: Efficacy Evaluation of Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy on Disease-free-survival (DFS) in Patients With Resectable Head and Neck Mucosal Melanoma
|
En recrutement
|
02 mars 2024
|
|
NCT05443087
|
Dosing of Various Multi Kinases Inhibitors Plasma Concentrations for Patients Treated for Their Advanced Digestive Cancer, With the Aim to Determine the Best Optimal Dose for Each Treatment, in the Future
|
En recrutement
|
02 mars 2024
|
|
NCT05031962
|
Porcine Acellular Dermal Matrix (PADM)-Assisted Implant-based Breast Reconstruction: a Prospective Observational Study
|
En recrutement
|
26 février 2024
|
|
NCT05431738
|
Esophageal Stent With or Without Anti-migration Device for Tumors of the Gastroesophageal Junction: Multicenter Randomized Controlled Study. ANTIMIG Study
|
En recrutement
|
26 février 2024
|
|
NCT04602377
|
Multicentric Non-randomized Phase II of Pembrolizumab in Combination With Etoposide-cisplatin-based Chemotherapy in First-line Small Cell Ovarian Carcinoma of Hypercalcemic Type (PembroSCCOHT)
|
En recrutement
|
23 février 2024
|
|
NCT04290663
|
Multicentric Phase III Trial Comparing Two Strategies in Intermediate-risk Differentiated Thyroid Cancer Patients: Systematic Radioiodine Administration Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up Based on Serum Tg Values and Diagnostic RAI Scintigraphy
|
En recrutement
|
22 février 2024
|
|
NCT03354936
|
A Multicenter Observational Cohort for HIV Infected Patients With a Cancer Treated by Immune-Checkpoint Inhibitors.
|
En recrutement
|
21 février 2024
|
|
NCT04055220
|
A Randomized, Placebo-controlled, Double-blinded, Multicentre Study Evaluating the Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas (REGOSTA)
|
En recrutement
|
21 février 2024
|
|
NCT03564340
|
A Phase 1/2 Study of REGN4018 (Ubamatamab), a MUC16×CD3 Bispecific Antibody, Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer or Other Recurrent MUC16+ Cancers
|
En recrutement
|
19 février 2024
|
|
NCT04268121
|
Phase II Study to Evaluate the Efficacy of 12-month Neoadjuvant Chemotherapy in Terms of Disease-free Survival in Patients With Localized Digestive Neuroendocrine Carcinomas (NEONEC)
|
En recrutement
|
18 février 2024
|
|
NCT05009927
|
Randomized, Multicentre, Phase II Study Evaluating the Interest of Imatinib Treatment Maintenance or Interruption After at Least 10 Years of Treatment in Patients With Locally Advanced/Metastatic Gastrointestinal Stromal Tumors (GISTs)
|
En recrutement
|
18 février 2024
|
|
NCT02584933
|
An Open-label, Multi-center, Phase IV Roll-over Study in Patients With ALK Positive Malignancies Who Have Completed a Novartis-sponsored Ceritinib (LDK378) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Ceritinib
|
En recrutement
|
17 février 2024
|
|
NCT03548428
|
Randomized Phase II, 2-arm Study of Immunomodulation with Atezolizumab Concomitant with High Dose Radiation (SBRT) Versus SBRT Alone in Patients with Oligometastatic Sarcomas
|
En recrutement
|
17 février 2024
|
|
NCT04954820
|
A Prospective Randomized Phase II Study Assess the Schema of Retreatment With Lutathera® ([177LU]LU-DOTA-TATE) in Patients With New Progression of Intestinal Well-differenciated Neuroendocrine Tumor
|
En recrutement
|
17 février 2024
|
|
NCT05233787
|
A Phase III Randomized Trial Evaluating the Tailored Versus the Systematic Use of Defunctioning Stoma After Total Mesorectal Excision for Rectal Cancer
|
En recrutement
|
16 février 2024
|
|
NCT04428151
|
A Phase 2, Randomized, Open-label Three-arm Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) That Have Progressed After Platinum Therapy and Immunotherapy (PD-1/PD-L1 Inhibitors) (LEAP-009)
|
En recrutement
|
16 février 2024
|
|
NCT05871164
|
Longitudinal, Prospective, French, Multicenter Cohort Study on Pancreatic Radiofrequency (RAFPAN2)
|
En recrutement
|
15 février 2024
|
|
NCT05730036
|
An Open-label, Randomized, Phase 3 Study of Linvoseltamab (REGN5458; Anti- BCMA x Anti-CD3 Bispecific Antibody) Versus the Combination of Elotuzumab, Pomalidomide, and Dexamethasone (EPd), in Patients With Relapsed/Refractory Multiple Myeloma (LINKER-MM3)
|
En recrutement
|
13 février 2024
|
|
NCT05352672
|
A Phase 3 Trial of Fianlimab (REGN3767, Anti-LAG-3) + Cemiplimab Versus Pembrolizumab in Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
|
En recrutement
|
12 février 2024
|
|
NCT02885753
|
Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver
|
En recrutement
|
04 février 2024
|
|
NCT05533775
|
A Phase I/II, Open-Label, Single-Arm, Two-Part Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Glofitamab in Monotherapy and in Combination With Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
|
En recrutement
|
17 janvier 2024
|
|
NCT06160596
|
Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis: A 3 Cohorts Case Control Matched Study
|
En recrutement
|
08 décembre 2023
|
|
NCT04262687
|
Pembrolizumab in Combination With Xelox Bevacizumab in Patients With Microsatellite Stable Mestatic Colorectal Cancer and a High Immune Infiltrate : a Proof of Concept Study
|
Statut inconnu
|
20 mars 2023
|
|
NCT05157555
|
Quality of Life in Patients After Pharyngolaryngectomy (LARYNG-QDV)
|
Statut inconnu
|
20 mars 2023
|
|
NCT03848052
|
Epidemiological Strategy and Medical Economic (ESME) Research Program / Academic Real World Data Platform: Evolution of the Therapeutic Care in Lung Cancer in France Since 2015
|
En recrutement
|
18 janvier 2023
|
|
NCT03275311
|
Epidemiological Strategy and Medical Economic (ESME) Research Program / Academic Real World Database: Evolution of the Therapeutic Care in Metastatic Breast Cancer Across the French Comprehensive Cancer Centers From 2008 (ESME-MBC)
|
En recrutement
|
18 janvier 2023
|
|
NCT01620372
|
Constitution d'Une Cohorte Nationale rétrospective de Survivants d'un Cancer Solide de l'Enfant diagnostiqué Avant 2000
|
En recrutement
|
18 janvier 2023
|
|
NCT04863547
|
Severity of the New UK SARS-Cov2 Variant in COVID-19 Infection
|
Statut inconnu
|
18 janvier 2023
|
|
NCT03750994
|
Economic Evaluation of Innovative Molecular Analyses in Onco-haematology (PRME-K 2016)
|
Statut inconnu
|
08 novembre 2022
|
|
NCT02724696
|
French National Observatory of Patients With Thymic Epithelial Tumor
|
En recrutement
|
08 novembre 2022
|
|
NCT00003122
|
Phase II Trial of Surgery as the Only Treatment for INSS Stage 2A & 2B Neuroblastoma
|
Statut inconnu
|
08 novembre 2022
|
|
NCT05272358
|
Economic Evaluation of Early Management of Sarcoma Patients by the Sarcoma Reference Network (NETSARC), Exploration of Organisational and Financial Constraints
|
Statut inconnu
|
08 novembre 2022
|
|
NCT01704716
|
High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN)
|
En recrutement
|
08 novembre 2022
|